Molecular modeling of blood-brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous system.

For drugs that act in the brain, the blood-brain barrier (BBB) is a considerable physical barrier which influences the distribution of drugs to the brain. The BBB is essentially impermeable for hydrophilic and/or charged compounds. Nutrient membrane transporters have an important physiological role in the transport of essential substances across the BBB required for normal brain function. We and others have shown that these transporters may have utility as drug delivery vectors, thereby increasing brain distribution of these compounds via these systems. In this review, we evaluate molecular (in silico) models of BBB transport proteins. Few BBB membrane transporters have been crystallized, but their crystal structures have a possibility for use in homology modeling. Other techniques commonly used are 2D quantitative structure-activity relationships (QSAR), as well as 3D-QSAR techniques including comparative molecular field analysis (CoMFA) and comparative similarity index analysis (CoMSIA). Each of these models provides valuable information for ascertaining their potential basis for BBB transport and brain drug delivery.

[1]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[2]  W. Geldenhuys,et al.  Molecular modeling studies on the active binding site of the blood-brain barrier choline transporter. , 2004, Bioorganic & medicinal chemistry letters.

[3]  P. Lockman,et al.  The Transport of Choline , 2002, Drug development and industrial pharmacy.

[4]  E. Lien,et al.  Structure–activity relationship: analyses of p‐glycoprotein substrates and inhibitors , 2003, Journal of clinical pharmacy and therapeutics.

[5]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[6]  Peter W. Swaan,et al.  Structural Determinants of P-Glycoprotein-Mediated Transport of Glucocorticoids , 2003, Pharmaceutical Research.

[7]  W. Pardridge,et al.  Blood-brain barrier genomics and the use of endogenous transporters to cause drug penetration into the brain. , 2003, Current opinion in drug discovery & development.

[8]  U. Norinder,et al.  Computational approaches to the prediction of the blood-brain distribution. , 2002, Advanced drug delivery reviews.

[9]  I. Tamai,et al.  Transporter-mediated permeation of drugs across the blood-brain barrier. , 2000, Journal of pharmaceutical sciences.

[10]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[11]  G. Goldenberg,et al.  Membrane transport of alkylating agents. , 1980, Pharmacology & therapeutics.

[12]  W. Pardridge Molecular biology of the blood-brain barrier. , 2005, Molecular biotechnology.

[13]  Gerry McDermott,et al.  Structural Basis of Multiple Drug-Binding Capacity of the AcrB Multidrug Efflux Pump , 2003, Science.

[14]  Y. Sawada,et al.  Characteristics of Choline Transport Across the Blood-Brain Barrier in Mice: Correlation with In Vitro Data , 2000, Pharmaceutical Research.

[15]  S. Ekins,et al.  Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. , 2002, Molecular pharmacology.

[16]  A. Garnier-Suillerot,et al.  A Structural Model for the Open Conformation of the mdr1 P-glycoprotein Based on the MsbA Crystal Structure* , 2003, Journal of Biological Chemistry.

[17]  Ingebrigt Sylte,et al.  Molecular model of the neural dopamine transporter , 2003, J. Comput. Aided Mol. Des..

[18]  J R Chretien,et al.  Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. , 1998, Journal of drug targeting.

[19]  P. Lockman,et al.  The blood-brain barrier choline transporter as a brain drug delivery vector. , 2003, Life sciences.

[20]  A. Ravna,et al.  Structures and Models of Transporter Proteins , 2004, Journal of Pharmacology and Experimental Therapeutics.

[21]  S. Ekins,et al.  Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. , 2002, Molecular pharmacology.

[22]  R. Bendayan,et al.  Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. , 2001, Pharmacological reviews.

[23]  B. McEwen,et al.  Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. , 2001, Annual review of pharmacology and toxicology.

[24]  Takashi Okuda,et al.  Identification and characterization of the high-affinity choline transporter , 2000, Nature Neuroscience.

[25]  M. Brightman,et al.  Morphology of blood-brain interfaces. , 1977, Experimental eye research.

[26]  Emi Nakashima,et al.  New approaches to in vitro models of blood-brain barrier drug transport. , 2003, Drug discovery today.

[27]  A. Ray,et al.  In silico strategies for modeling membrane transporter function. , 2005, Drug discovery today.

[28]  N. Shaik,et al.  Drug efflux transporters in the CNS. , 2003, Advanced drug delivery reviews.

[29]  D. E. Clark In silico prediction of blood-brain barrier permeation. , 2003, Drug discovery today.

[30]  W. Pardridge Blood-brain barrier drug targeting: the future of brain drug development. , 2003, Molecular interventions.

[31]  D. Dwyer Molecular modeling and molecular dynamics simulations of membrane transporter proteins. , 2003, Methods in molecular biology.